Analysis of Pfizer's financial performance, acquisitions, and future prospects, highlighting key challenges and opportunities ...

More than a few companies that did well in the past are out of favor with investors. And that could spell opportunity.

Shares of several COVID-19 vaccine developers sank fast enough to reflect investor jitters about vaccine policy given RFK’s ...

BioNTech said that BNT327 has the "potential to replace current checkpoint inhibitor standard of care treatments for solid ...

Although it is seeing a downturn in sales and profits, German biotech BioNTech (Nasdaq: BNTX) is continuing to acquire assets ...

Yes, you can get your flu and COVID-19 shots at the same time. Don't call them boosters -- they're not just another dose of ...

The selection of vaccine sceptic Robert F Kennedy Jr by US President-elect Donald Trump to head the Department of Health and ...

Looking at options history for BioNTech BNTX we detected 11 trades. If we consider the specifics of each trade, it is ...

One stock yields 6% today. Another has grown its dividend by 460% over the past decade. Both are blue chip bargains to buy ...

The company’s updated guidance for revenue includes approximately $10.5B in anticipated revenues for Comirnaty and Paxlovid, approximately $5B and $5.5B, respectively. Including the contribution ...

Pfizer has a pill it's developing called danuglipron, which is in early-stage trials but has demonstrated that it's ...

Operator Good day, everyone, and welcome to Pfizer's third quarter 2024 earnings conference call. Today's call is being ...